Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Regina, Berkovich"'
Autor:
Antonina Dolgorukova, Ekaterina Protsenko, Julia Isaeva, Victoria Gagloeva, Elena Verbitskaya, Regina Berkovich, Alexey Y. Sokolov
Publikováno v:
European Journal of Neuroscience.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::67221ff0d6ef4f8ecce62127270ade92
https://doi.org/10.1111/ejn.16030
https://doi.org/10.1111/ejn.16030
Autor:
John Foley, Regina Berkovich, Mark Gudesblatt, Elizabeth Luce, Beth Schneider, Carl de Moor, Shirley Liao, Lily Lee, Karthik Bodhinathan, Robin Avila
Publikováno v:
Neurodegenerative disease management.
Aim: Patients with relapsing–remitting multiple sclerosis (RRMS) treated with natalizumab have anecdotally reported a ‘feel-good experience’ (FGE). The authors characterized the FGE using survey data from patients with RRMS treated with nataliz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7bec8f1fc3fadb672795aab80705e29
https://pubmed.ncbi.nlm.nih.gov/36285716
https://pubmed.ncbi.nlm.nih.gov/36285716
Autor:
Regina Berkovich, Rohit Bakshi, Lilyana Amezcua, Robert C. Axtell, Steven Y. Cen, Shahamat Tauhid, Mohit Neema, Lawrence Steinman
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 10 (2017)
Background: The objective of this study was to evaluate monthly intramuscular adrenocorticotropic hormone (ACTH) gel versus intravenous methylprednisolone (IVMP) add-on therapy to interferon β for breakthrough disease in patients with relapsing form
Externí odkaz:
https://doaj.org/article/669da6c82be84a56bc0897534748db53
Autor:
Regina, Berkovich, Donald, Negroski, Daniel, Wynn, Daniel, Sellers, Kristen G, Bzdek, Alex L, Lublin, Andreea M, Rawlings, Cuc, Quach, Danelle P, Wells, Melanie, Dumlao, Adriana, Bora, Anthony E, Ranno, Kevin Lin, Luo, Jeffrey, Chavin, Le H, Hua, Daniel, Becker
Publikováno v:
Multiple Sclerosis and Related Disorders. 70:104472
The prevalence of multiple sclerosis (MS) in older people is increasing due to population aging and availability of effective disease-modifying therapies (DMTs). Treating older people with MS is complicated by age-related and MS-related comorbidities
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acf448432d8a889276fa152f57ecd218
https://doi.org/10.1016/j.msard.2022.104472
https://doi.org/10.1016/j.msard.2022.104472
Autor:
Regina Berkovich
Publikováno v:
Clinical Neuropharmacology. 43:7-14
OBJECTIVES Neuromyelitis optica (NMO) has a complex pathology. Clinical symptoms, derived from damage to optic nerves and spinal cord, cause optic neuritis and/or longitudinally extensive myelitis. Treatment options are limited. We assessed adrenocor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04fc6609c37c1564085e988fd83c921d
https://doi.org/10.1097/wnf.0000000000000373
https://doi.org/10.1097/wnf.0000000000000373
Autor:
Regina Berkovich, Mark A. Agius
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 7 (2014)
Acute and subacute inflammation, the mechanisms by which demyelination and axonal loss occur in multiple sclerosis (MS), result from the migration of activated immune cells into the central nervous system parenchyma. The triggering antigen is unknown
Externí odkaz:
https://doaj.org/article/7ba8534317a14f219c2ce8323a9bc728
Autor:
Patricia A. Russo, Rolin L Wade, Edward Fox, Magdaliz Gorritz, Regina Berkovich, Lauren Bartolome, Kristen Johnson, Yao Ding, Annette Okai, Wendy Su
Publikováno v:
Journal of medical economics. 24(1)
In clinical trials, disability progression in multiple sclerosis (MS) is measured by the Kurtzke expanded disability status scale (EDSS), which is not captured in routine clinical care in the U.S. This study developed a claims-based disability score
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cd7637bd1df416ff7fbc55d1a5a8adf
https://pubmed.ncbi.nlm.nih.gov/33297816
https://pubmed.ncbi.nlm.nih.gov/33297816
Autor:
Topaz investigators, Christopher LaGanke, Samuel F. Hunter, Zia Choudhry, Tjalf Ziemssen, Giancarlo Comi, Bart Van Wijmeersch, Daniel Pelletier, Ann D Bass, Sven Schippling, Care-Ms I, Care-Ms Ii, Camms, Lívia Sousa, Anthony Traboulsee, Regina Berkovich, Volker Limmroth, Carlo Pozzilli, Barry A Singer, Bernard M. J. Uitdehaag, Sara Eichau, Jeremy Hobart, Nadia Daizadeh
Publikováno v:
CNS Drugs
Ziemssen, T, Bass, A D, Berkovich, R, Comi, G, Eichau, S, Hobart, J, Hunter, S F, LaGanke, C, Limmroth, V, Pelletier, D, Pozzilli, C, Schippling, S, Sousa, L, Traboulsee, A, Uitdehaag, B M J, Van Wijmeersch, B, Choudhry, Z, Daizadeh, N, Singer, B A & CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ investigators 2020, ' Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease : Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study ', CNS Drugs, vol. 34, no. 9, pp. 973-988 . https://doi.org/10.1007/s40263-020-00749-x
CNS Drugs, 34(9), 973-988. Adis International Ltd
Ziemssen, T, Bass, A D, Berkovich, R, Comi, G, Eichau, S, Hobart, J, Hunter, S F, LaGanke, C, Limmroth, V, Pelletier, D, Pozzilli, C, Schippling, S, Sousa, L, Traboulsee, A, Uitdehaag, B M J, Van Wijmeersch, B, Choudhry, Z, Daizadeh, N, Singer, B A & CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ investigators 2020, ' Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease : Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study ', CNS Drugs, vol. 34, no. 9, pp. 973-988 . https://doi.org/10.1007/s40263-020-00749-x
CNS Drugs, 34(9), 973-988. Adis International Ltd
Background Alemtuzumab efficacy versus subcutaneous interferon-beta-1a (SC IFNB-1a) was demonstrated over 2 years in patients with relapsing-remitting multiple sclerosis, with continued efficacy over 7 additional years. Alemtuzumab is included as a r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a884d772f173242e654daa2c546c1549
https://pubmed.ncbi.nlm.nih.gov/32710396
https://pubmed.ncbi.nlm.nih.gov/32710396
Autor:
Giancarlo Comi, Raed Alroughani, Aaron L Boster, Ann D Bass, Regina Berkovich, Óscar Fernández, Ho Jin Kim, Volker Limmroth, Jan Lycke, Richard AL Macdonell, Basil Sharrack, Barry A Singer, Patrick Vermersch, Heinz Wiendl, Tjalf Ziemssen, Alan Jacobs, Nadia Daizadeh, Claudio E Rodriguez, Anthony Traboulsee, Darren P. Baker, Ericka M. Bueno, Colin Mitchell, Rebecca L. Orndorff, Valerie P. Zediak
Publikováno v:
Multiple Sclerosis (Houndmills, Basingstoke, England)
Background: Alemtuzumab is given as two annual courses. Patients with continued disease activity may receive as-needed additional courses. Objective: To evaluate efficacy and safety of additional alemtuzumab courses in the CARE-MS (Comparison of Alem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5f74ae046391f8852664dc6fc783f1a
https://hdl.handle.net/10668/14739
https://hdl.handle.net/10668/14739
Publikováno v:
Neurology® Neuroimmunology & Neuroinflammation
article-version (Version of Record) 3
article-version (Version of Record) 3
ObjectiveTo present observations on administration of natalizumab to 18 patients with the comorbid MS and psoriasis, who represented a full subset of patients with such comorbidity within the patient records available.MethodsA retrospective analysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7707dae71a0ee9b79ad7b1b2452ded81
https://doi.org/10.1212/nxi.0000000000000961
https://doi.org/10.1212/nxi.0000000000000961